As of Thursday close, Emergent BioSolutions Inc.’s (NYSE:EBS) stock was down -$0.21, moving down -5.75 percent to $3.44. The average number of shares traded per day over the past five days has been 4,193,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.70 fall in that time frame. In the last twenty days, the average volume was 3,647,135, while in the previous 50 days, it was 2,632,158.
Since last month, EBS stock retreated -23.21%. Shares of the company fell to $3.40 on 09/21/23, the lowest level in the past month. A 52-week high of $22.35 was reached on 02/21/23 after having rallying from a 52-week low of $3.53. Since the beginning of this year, EBS’s stock price has dropped by -70.87% or -$8.37, and marked a new high 11 times. However, the stock has declined by -84.61% since its 52-week high.
EBS stock investors should be aware that Emergent BioSolutions Inc. (EBS) stock had its last reported insider trading activity 112 days ago on Jun 02. Zoon Kathryn C, the Director of the company, disposed of 1,830 shares for $8.35 on Jun 02. It resulted in a $15,280 divestment by the insider. Zoon Kathryn C sold 1,700 shares at an average price of $8.38 on May 25. The insider now owns 51,801 shares following the transaction. On Nov 25, Director Richard Ronald sold 1,912 shares at $11.94 apiece. The transaction was valued at $22,829.
Valuation Metrics
The stock’s beta is 0.91. Besides these, the trailing price-to-sales (P/S) ratio of 0.17, the price-to-book (PB) ratio of 0.18.
Financial Health
In the three months ended June 29, Emergent BioSolutions Inc.’s quick ratio stood at 0.60, while its current ratio was 1.10, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.47, and the total debt-to-equity ratio was 0.94. On the profitability front, the trailing twelve-month gross margin is 33.50% percent. In the year ended June 29, EBITDA margin amounted to -1.13%, whereas operating margins totaled -44.10%. Based on annual data, EBS earned $427.2 million in gross profit and brought in $1.12 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -6.30%. Return on equity (ROE) for the past 12 months was -48.70%.
In Emergent BioSolutions Inc.’s quarter-end financial report for June 29, it reported total debt of $448.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EBS’s revenue rose 28.17% to $165.1 million during the quarter, while net income inched up to $337.9 million. While analysts expected Emergent BioSolutions Inc. to report -$0.49 quarterly earnings, the actual figure was -$1.06 per share, beating the consensus estimate by -116.30%. During the quarter, the company generated -$251.1 million in EBITDA. The liabilities of Emergent BioSolutions Inc. were 1.22 billion at the end of its most recent quarter ended June 29, and its total debt was $919.9 million. The value of shareholders’ equity is $51.81 million.
Technical Picture
This quick technical analysis looks at Emergent BioSolutions Inc.’s (EBS) price momentum. With a historical volatility rate of 55.13%, the RSI 9-day stood at 25.93% on 21 September.
With respect to its five-day moving average, the current Emergent BioSolutions Inc. price is down by -16.91% percent or -$0.70. At present, EBS shares trade -24.06% below its 20-day simple moving average and -61.04% percent below its 100-day simple moving average. However, the stock is currently trading approximately -53.39% below its SMA50 and -71.33% below its SMA200.
Stochastic coefficient K was 7.08% and Stochastic coefficient D was 8.13%, while ATR was 0.36. Given the Stochastic reading of 2.21% for the 14-day period, the RSI (14) reading has been calculated as 28.79%. As of today, the MACD Oscillator reading stands at -0.27, while the 14-day reading stands at -0.55.
Analyst Ratings
Emergent BioSolutions Inc. downgraded its rating on Emergent BioSolutions Inc. (NYSE: EBS) to a Hold in a note to investors on August 29, 2023. The analysts firm previously had a Buy rating on the stock.Emergent BioSolutions Inc. (EBS) has been rated Overweight by analysts. According to 0 brokerage firms, EBS is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Emergent BioSolutions Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $13.50, the current consensus forecast for the stock is $11.00 – $22.00. Based on these forecasts, analysts predict Emergent BioSolutions Inc. (EBS) will achieve an average price target of $15.50.
